leisure time -WSS

leisure time

author：knowledge 2025-09-30 00:35:19 - browse：29239

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Vertex non

hotspot

WSS

FDA struggles to regulate food additives, sometimes for decades

Pharmacists can make shortage drugs, but at what cost?

How climate

STAT Readout Newsletter: Today's biggest biotech updates

Pharmacists can make shortage drugs, but at what cost?

STAT Summit: How a Chicago ER doctor tackles gun violence

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Pancreatic cancer early detection could be helped by AI

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

White House pharmacy plagued with problems, investigation finds

Drug repurposing or repositioning? The language matters

Why health workers in Gaza are injured or die at high rates

In age of alternative facts, a scholarly course on calling out crap

Humana’s losses in Medicare Advantage tank its stock

Jerome Adams on the need for new antivirals for Covid

Reconstructing family trees of blood cells may help predict disease

focus

Philips to halt sales of sleep apnea machines in U.S.

HHS leader on health, climate change and biopharma emissions

10 reasons why health care startups fail

Pharmacists can make shortage drugs, but at what cost?

Reconstructing family trees of blood cells may help predict disease

Reconstructing family trees of blood cells may help predict disease

hotspot

explore

hotspot

leisure time